BioPharmSignal logoBioPharmSignal

Biotech News

Adaptive Biotechnologies Showcases Leadership in Hematology-Oncology MRD with New clonoSEQ® Data Driving Treatment Interventions at 2025 ASH Annual Meeting

Adaptive Biotechnologies (ADPT)Adaptive Biotechnologies2026-06-25 13:46 ESTCommercial

SEATTLE, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, announced growing interventional use of

Open original release

Related news

ADPTAdaptive Biotechnologies2026-06-25 13:46 EST

Adaptive Biotechnologies Corporation Prices Upsized $300 Million Convertible Senior Notes Offering

ADPTAdaptive Biotechnologies2026-06-25 13:46 EST

Adaptive Biotechnologies Announces Plan to Separate Its MRD and Immune Medicine Businesses

ADPTAdaptive Biotechnologies2026-06-25 13:46 EST

Adaptive Biotechnologies Corporation Announces Proposed Convertible Senior Notes Offering

ADPTAdaptive Biotechnologies2026-06-25 13:46 EST

At ASCO and EHA 2026, New Data Reinforce the Pivotal Role of clonoSEQ® MRD Testing Across Hematology Clinical Practice and Research

ADPTAdaptive Biotechnologies2026-06-25 13:46 EST

Adaptive Biotechnologies to Participate in Jefferies Fireside Chat Series on Minimal Residual Disease

ADPTAdaptive Biotechnologies2026-06-25 13:46 EST

Adaptive Biotechnologies Announces Two Immune Receptor Licensing Agreements with Pfizer

ADPTAdaptive Biotechnologies2026-06-25 13:46 EST

Adaptive Biotechnologies to Present at the 44th Annual J.P. Morgan Healthcare Conference

ADPTAdaptive Biotechnologies2026-06-25 13:46 EST

Adaptive Biotechnologies Announces Preliminary Fourth Quarter and Full Year 2025 Results

ADPTAdaptive Biotechnologies2026-06-25 13:46 EST

Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2025 Financial Results on February 5, 2026

ADPTAdaptive Biotechnologies2026-06-25 13:46 EST

Adaptive Biotechnologies to Participate in Upcoming Investor Conferences

View all latest news

Adaptive Biotechnologies

Adaptive Biotechnologies is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.

Recent company news

ADPTAdaptive Biotechnologies2026-06-26 08:52 EST

Adaptive Biotechnologies Corporation Prices Upsized $300 Million Convertible Senior Notes Offering

ADPTAdaptive Biotechnologies2026-06-26 08:52 EST

Adaptive Biotechnologies Announces Plan to Separate Its MRD and Immune Medicine Businesses

ADPTAdaptive Biotechnologies2026-06-26 08:52 EST

Adaptive Biotechnologies Corporation Announces Proposed Convertible Senior Notes Offering

ADPTAdaptive Biotechnologies2026-06-26 08:52 EST

At ASCO and EHA 2026, New Data Reinforce the Pivotal Role of clonoSEQ® MRD Testing Across Hematology Clinical Practice and Research

ADPTAdaptive Biotechnologies2026-06-26 08:52 EST

Adaptive Biotechnologies Showcases Leadership in Hematology-Oncology MRD with New clonoSEQ® Data Driving Treatment Interventions at 2025 ASH Annual Meeting

Stock data

Close
—
Market cap
—
Exchange
NASDAQ
Sector
Biotechnology
Location
United States